These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 35945547)
1. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial. Chiba Y; Sudo K; Kojima Y; Okuma H; Kohsaka S; Machida R; Ichimura M; Anjo K; Kurishita K; Okita N; Nakamura K; Kinoshita I; Takahashi M; Matsubara J; Kusaba H; Yonemori K; Takahashi M BMC Cancer; 2022 Aug; 22(1):869. PubMed ID: 35945547 [TBL] [Abstract][Full Text] [Related]
2. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models. Watanabe Miyano S; Yamamoto Y; Kodama K; Miyajima Y; Mikamoto M; Nakagawa T; Kuramochi H; Funasaka S; Nagao S; Sugi NH; Okamoto K; Minoshima Y; Nakatani Y; Karoji Y; Ohashi I; Yamane Y; Okada T; Matsushima T; Matsui J; Iwata M; Uenaka T; Tsuruoka A Mol Cancer Ther; 2016 Nov; 15(11):2630-2639. PubMed ID: 27535969 [TBL] [Abstract][Full Text] [Related]
3. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Koyama T; Shimizu T; Iwasa S; Fujiwara Y; Kondo S; Kitano S; Yonemori K; Shimomura A; Iizumi S; Sasaki T; Furuse J; Yamamoto N Cancer Sci; 2020 Feb; 111(2):571-579. PubMed ID: 31797489 [TBL] [Abstract][Full Text] [Related]
4. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822 [TBL] [Abstract][Full Text] [Related]
5. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring Voss MH; Hierro C; Heist RS; Cleary JM; Meric-Bernstam F; Tabernero J; Janku F; Gandhi L; Iafrate AJ; Borger DR; Ishii N; Hu Y; Kirpicheva Y; Nicolas-Metral V; Pokorska-Bocci A; Vaslin Chessex A; Zanna C; Flaherty KT; Baselga J Clin Cancer Res; 2019 May; 25(9):2699-2707. PubMed ID: 30745300 [TBL] [Abstract][Full Text] [Related]
6. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Rodón J; Damian S; Furqan M; García-Donas J; Imai H; Italiano A; Spanggaard I; Ueno M; Yokota T; Veronese ML; Oliveira N; Li X; Gilmartin A; Schaffer M; Goyal L Nat Med; 2024 Jun; 30(6):1645-1654. PubMed ID: 38710951 [TBL] [Abstract][Full Text] [Related]
7. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082 [TBL] [Abstract][Full Text] [Related]
8. Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Grivas P; Garralda E; Meric-Bernstam F; Mellinghoff IK; Goyal L; Harding JJ; Dees EC; Bahleda R; Azad NS; Karippot A; Kurzrock R; Tabernero J; Kononen J; Ng MCH; Mehta R; Uboha NV; Bigot F; Boni V; Bowyer SE; Breder V; Cervantes A; Chan N; Cleary JM; Dhawan M; Eefsen RL; Ewing J; Graham DM; Guren TK; Won Kim J; Koynov K; Oh DY; Redman R; Yen CJ; Spetzler D; Roubaudi-Fraschini MC; Nicolas-Metral V; Ait-Sarkouh R; Zanna C; Ennaji A; Pokorska-Bocci A; Flaherty KT Clin Cancer Res; 2024 Oct; 30(20):4572-4583. PubMed ID: 38771739 [TBL] [Abstract][Full Text] [Related]
9. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168 [TBL] [Abstract][Full Text] [Related]
10. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351 [TBL] [Abstract][Full Text] [Related]
11. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180 [TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Erdafitinib in Patients With Tumors With Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651 [TBL] [Abstract][Full Text] [Related]
13. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. Facchinetti F; Hollebecque A; Bahleda R; Loriot Y; Olaussen KA; Massard C; Friboulet L Clin Cancer Res; 2020 Feb; 26(4):764-774. PubMed ID: 31585937 [TBL] [Abstract][Full Text] [Related]
14. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034 [TBL] [Abstract][Full Text] [Related]
15. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Roskoski R Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593 [TBL] [Abstract][Full Text] [Related]
16. Targeting FGFR Signaling in Cancer. Touat M; Ileana E; Postel-Vinay S; André F; Soria JC Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430 [TBL] [Abstract][Full Text] [Related]
17. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Lassman AB; Sepúlveda-Sánchez JM; Cloughesy TF; Gil-Gil MJ; Puduvalli VK; Raizer JJ; De Vos FYF; Wen PY; Butowski NA; Clement PMJ; Groves MD; Belda-Iniesta C; Giglio P; Soifer HS; Rowsey S; Xu C; Avogadri F; Wei G; Moran S; Roth P Clin Cancer Res; 2022 Jun; 28(11):2270-2277. PubMed ID: 35344029 [TBL] [Abstract][Full Text] [Related]
18. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457 [TBL] [Abstract][Full Text] [Related]
20. A sensitive assay for the determination of E7090, a novel selective inhibitor of fibroblast growth factor receptors, and its metabolite in human plasma by UPLC-MS/MS with at-column dilution. Mano Y; Nitanai I; Hotta K J Pharm Biomed Anal; 2024 Jan; 238():115866. PubMed ID: 37995478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]